Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference6 articles.
1. Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
2. Irinotecan Treatment for Recurrent Malignant Glioma Using an Every-3-Week Regimen
3. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.
4. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Cited by 105 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study;Journal of Korean Medical Science;2024
2. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma;Journal of Clinical Oncology;2023-11-10
3. Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model;Frontiers in Immunology;2023-01-10
4. A Potential New Treatment for High-Grade Glioma: A Study Assessing Repurposed Drug Combinations against Patient-Derived High-Grade Glioma Cells;Cancers;2022-05-25
5. A retrospective analysis of irinotecan and bevacizumab combination therapy in recurrent high-grade glioma and glioblastoma multiforme: Single-institute experience;International Journal of Neurooncology;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3